NCT00052351View on ClinicalTrials.gov

Vaccine Therapy Plus Sargramostim and Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

September 30, 2002

Study Completion Date

October 31, 2007

Conditions
Breast Cancer
Interventions
BIOLOGICAL

recombinant fowlpox-CEA(6D)/TRICOM vaccine

BIOLOGICAL

recombinant vaccinia-CEA(6D)-TRICOM vaccine

BIOLOGICAL

sargramostim

DRUG

cyclophosphamide

DRUG

doxorubicin hydrochloride

DRUG

paclitaxel

RADIATION

radiation therapy

Trial Locations (2)

20892

Center for Cancer Research, Bethesda

20892-1182

Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00052351 - Vaccine Therapy Plus Sargramostim and Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer | Biotech Hunter | Biotech Hunter